Developing Osteoarthritis Drugs in Times of ”Rapidly Progressive Osteoarthritis”
Join us to discuss rapidly progressive osteoarthritis (RPOA) and challenges of designing and executing Osteoarthritis clinical trials.
The webinar “Rapidly Progressive Osteoarthritis (RPOA) and Challenges of Designing and Executing Osteoarthritis Clinical Trials” has already taken place. However, for those interested in the valuable insights shared during this event, a recording may be available upon request.
This webinar focused on the challenges of designing osteoarthritis (OA) clinical trials, with a particular emphasis on accounting for patients who may develop rapidly progressive osteoarthritis (RPOA). Key discussion points included:
-
Regulatory perspective and future directions in knee OA drug development
-
Observational radiographic features that may lead to prompt diagnosis of RPOA
-
Design of clinical trials of osteoarthritis and use of imaging in identifying RPOA
The expert panel featured:
-
Prof. Mikael Boesen: Professor of musculoskeletal imaging with 20 years of international experience in clinical research on inflammatory and degenerative joint diseases.
-
Dr. Lee Simon: Rheumatologist, physician, and research scientist with extensive drug development experience, including service as a director of an FDA division.
-
Dr. Olga Kubassova (Moderator): CEO of IAG, Image Analysis Group, with expertise in quantitative imaging and development of novel efficacy methodologies using AI and Machine Learning.
The webinar highlighted the importance of understanding RPOA and incorporating appropriate imaging strategies in clinical trial design to exclude at-risk patients and monitor patient safety. This approach is crucial for ensuring accurate trial outcomes and patient safety in osteoarthritis drug development.
For those interested in accessing the webinar recording or learning more about IAG’s services in AI-powered drug development and precision medicine for osteoarthritis, please contact Image Analysis Group (IAG) directly through their official channels.